deltatrials
Completed PHASE3 NCT00720382

A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis

Active Controlled Trial of the Safety and Tolerability of MP 03-036 (Astepro 0.15%) in Patients With Perennial Allergic Rhinitis

Sponsor: Meda Pharmaceuticals

Conditions Perennial Allergic Rhinitis
Interventions 0.15% azelastine hydrochloride Mometasone furoate
Updated 7 times since 2017 Last updated: May 4, 2015 Started: Mar 31, 2007 Primary completion: Jun 30, 2008 Completion: Jul 31, 2008

A PHASE3 clinical study on Perennial Allergic Rhinitis, this trial is completed. The trial is conducted by Meda Pharmaceuticals and has accumulated 7 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Meda Pharmaceuticals
Data source: Meda Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States, Austin, United States, Blue Bell, United States, Charleston, United States, Cincinnati, United States, Collegeville, United States, Colorado Springs, United States, Dallas, United States, Edmond, United States, El Paso, United States and 43 more location s